Literature DB >> 31064625

Capacity of Abbott RealTime MTB RIF/INH to detect rifampicin- and isoniazid-resistant tuberculosis.

S Hofmann-Thiel1, N Molodtsov2, C Duffner2, A Kadyrov3, G Kalmambetova4, O Kabirov5, A Rajabov6, N Parpieva7, Z Sayfutdinov8, M Vogel2, H Vogel3, U Antonenka2, H Hoffmann1.   

Abstract

<sec id="st1"> <title>BACKGROUND</title> Abbott RealTime MTB RIF/INH Resistance (RT RIF/INH) is a new assay for the detection of resistance to rifampicin (RIF) and isoniazid (INH) in tuberculosis (TB) patients. </sec> <sec id="st2"> <title>OBJECTIVE</title> To evaluate the capacity of RT RIF/INH to detect resistance-associated mutations in target genes. </sec> <sec id="st3"> <title>METHODS</title> A total of 311 Mycobacterium tuberculosis strains that had been pre-characterised using genotypic methods (GenoType® MTBDRplus, Sanger sequencing) and phenotypic drug susceptibility testing were subjected to DNA extraction on Abbott m2000sp and analysed using RT RIF/INH. Detection of heteroresistant mutations was studied with artificial mixtures of wild-type and mutant DNA. </sec> <sec id="st4"> <title>RESULTS</title> Overall sensitivity and specificity values of RT RIF/INH to detect resistance were respectively 87.2% and 98.4% for RIF and respectively 90.1% and 99.2% for INH. The capacity of RT RIF/INH to detect specific mutations was 100% for katG, inhA and frequent rpoB mutations, and 76% for rare rpoB mutations. Among the latter, two rare mutations were not consistently detected. With heteroresistant samples, RT RIF/INH reported resistance if samples contained at least 75-90% of mutant DNA. </sec> <sec id="st5"> <title>CONCLUSION</title> RT RIF/INH is a reliable high-throughput assay for the detection of RIF and INH resistance markers. The ability to detect INH resistance also may be of benefit in areas with high rates of INH-resistant, non-multidrug-resistant TB. </sec>.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31064625     DOI: 10.5588/ijtld.18.0615

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.

Authors:  Lesley Scott; Anura David; Lyndel Govender; Jan Furrer; Modiehi Rakgokong; Ziyaad Waja; Neil Martinson; Gabriel Eisenberg; Elizabeth Marlowe; Wendy Stevens
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

3.  A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB.

Authors:  Markus Beutler; Sara Plesnik; Marina Mihalic; Laura Olbrich; Norbert Heinrich; Samuel Schumacher; Michael Lindner; Ina Koch; Wolfgang Grasse; Christoph Metzger-Boddien; Sabine Hofmann-Thiel; Harald Hoffmann
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

4.  The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates.

Authors:  Anura David; Lyndel Singh; Pedro Da Silva; Lesley Scott; Wendy Stevens
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003

Review 5.  Revisiting the methods for detecting Mycobacterium tuberculosis: what has the new millennium brought thus far?

Authors:  Thales Alves Campelo; Paulo Rafael Cardoso de Sousa; Lucas de Lima Nogueira; Cristiane Cunha Frota; Paulo Renato Zuquim Antas
Journal:  Access Microbiol       Date:  2021-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.